Pathway Related Drug Resistance Potential Treatment Inhibitor targeted
MAPK pathway
Chemoresistance Radiation resistance Enzyme therapy resistance CH5126766 along with Eribulin Dual inhibitors Cobimetinib and Trametinib Brucein D (BD) RAF/MEK inhibitor68 MEK1/2 and MEK 569 p38 pathway70
PI3K/AKT/mTOR pathway
Chemotherapy Resistance Radiotherapy Resistance Gigantol Anilide Shikonin ester- M9. AZD5363 alongside 3,3’-Diindoylmethane Dietary phytochemicals Akt 73-75 Luminal A breast cancer cells 76
STAT 3 pathway
Radiotherapy Resistance Chemotherapy resistance Resveratrol Trastuzumab 6Br-6a STAT3 77-79
Wnt/beta-catenin pathway
Chemoresistance Radioresistance Immunotherapy resistance Tankyrase inhibitors such as XAV939 Introduction of truncated APC Axin degradation64 Lack of APC64
Hedgehog pathway
Chemoresistance Immunotherapy resistance Smo inhibitors like Vismodegib,Sonidegib, Saridegib and Taladegib Smo receptor80,81
Notch pathway
Chemoresistance Immunotherapy resistance Gamma-secretase inhibitors such as  Z-Leu-Leu-Nle-CHO Monoclonal antibodies like OMP-59R5 Gamma-secretase protein82,84 Notch 2/ Notch 3 receptors83